ISSN: 1080-6059
Marcelo B. Labruna,*
Maria Ogrzewalska,*
Jonas Moraes-Filho,* Paulina Lepe,† Jose Luis Gallegos,† and Javier López†
*University of São Paulo, São Paulo, Brazil; and †Alcantara
Veterinary Clinics, Santiago, Chile
Suggested citation for this article
To the Editor: Rickettsiosis due to Rickettsia felis is an emerging disease that has been reported worldwide (1). Fever, headache, myalgia, and macular rash have been attributed to R. felis infection in humans (1). In South America, R. felis infection in fleas (mostly Ctenocephalides spp.) has been reported only in Brazil, Peru, and Uruguay (2–3). Although a growing number of articles have reported that R. felis is transmitted by fleas, the acquisition mechanism of R. felis by vertebrates or uninfected fleas in nature remains unknown (4).
Cats experimentally exposed to R. felis–infected fleas have been shown to become seropositive (5). However, neither serologic nor molecular evidence of R. felis infection has been reported in cats under natural conditions, despite the fact that most C. felis fleas are infected by R. felis (6,7).
In November 2006, we investigated the presence of rickettsial DNA in 30 C. felis fleas randomly collected from 22 domestic cats privately owned and housed indoors in a single household in Santiago, Chile. To detect rickettsial DNA in each individual flea, PCRs were performed that targeted a 398-nt fragment of the rickettsial gltA gene and an 856-nt fragment of the rickettsial ompB gene (7,8).
A total of 21 individual fleas (70%) yielded expected PCR products for both gltA and ompB genes. PCR gltA products from the 21 fleas and ompB products from 5 fleas were subjected to DNA sequencing as described (7). The gltA partial sequences obtained from 21 fleas were identical, as were the ompB partial sequences from 5 fleas. These sequences were 100% identical to corresponding sequences in the R. felis genome (GenBank accession no. CP000053).
Blood serum samples were collected from the 22 cats and tested by indirect immunofluorescence assay (IFA) with crude antigens derived from 6 Rickettsia isolates from Brazil: R. bellii, R. amblyommii, R. rhipicephali, R. rickettsii, R. parkeri, and R. felis (7,9). Serum was considered to contain antibodies against rickettsiae if it displayed a reaction at 1:64 dilution. End-point titers against each Rickettsia species were determined by testing serial 2-fold serum dilutions. Reactive serum specimens were tested in 2 or 3 replications by 2 readers before the end-point titer was determined. Serum showing a Rickettsia species titer at least 4-fold higher than those observed for the other Ricketttsia species was considered homologous to the first Rickettsia species or to a very closely related genotype (7,9). In each slide, a nonreactive cat serum specimen (negative control) and a known reactive cat serum specimen (positive control) were tested at the 1:64 dilution (7).
IFA detected antibodies reactive with R. felis (titer >64) in 16 (72.7%) of 22 cats. Among those, 5 (22.7%) also reacted with R. rhipicephali, 4 (18.2%) with R. bellii, 3 (13.6%) with R. parkeri, 2 (9.1%) with R. rickettsii, and 1 (4.5%) with R. amblyommii. No serum reacted with any other Rickettsia species without reacting with R. felis (Table). Four cat serum specimens (cats 1, 3, 8, and 11) showed titers to R. felis at least 4-fold higher than those to any of the other 5 antigens. The antibody titers in these 4 animals were considered to have been stimulated by R. felis infection. For the remaining 12 seropositive cats, we could not discern whether R. felis had been the infection agent because the results displayed a single titer of 64 for R. felis or showed similar titers for other Rickettsia species.
We report 70% R. felis–infected fleas in this study on the basis of the concordant results of 2 PCR amplifications (gltA and ompB) and DNA sequencing. This infection rate is within the range (13.5%–90%) that has been reported for R. felis infecting Ctenocephalides fleas in Brazil and Uruguay (2,3,7). Sixteen (72.7%) cats contained R. felis–reactive antibodies; 4 of them showed titers to R. felis at least 4-fold higher than those to the other 5 rickettsial strains, findings that enabled us to technically conclude that these cats were exposed to R. felis or a closely related organism (1,7,9). Our finding of 70% R. felis infection in fleas infesting the cats indicates that cats acquired the infection through infected fleas. However, the mechanism of R. felis transmission by fleas is yet to be demonstrated under experimental conditions.
To our knowledge, the presence of R. felis, or a spotted fever group Rickettsia species, has not been reported in Chile. Recent investigations have provided clinical and serologic evidence of canine (10) and human (K. Abarca and J. Lopez, unpub. data) infection by spotted fever rickettsia in Chile, confirmed by IFA that used R. conorii commercial antigen. Since substantial serologic cross-reaction occurs between R. conorii and R. felis antigens (1), R. felis could be causing infection in dogs or humans in Chile.
This research was financially supported by Clinica Veterinária Alcantara (Chile), Fundação de Amparo à Pesquisa do Estado de São Paulo (Brazil), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brazil).
Labruna MB, Ogrzewalska M, Moraes-Filho J, Lepe P, Gallegos JL, López J. Rickettsia felis in Chile [letter]. Emerg Infect Dis [serial on the Internet]. 2007 Nov [date cited]. Available from http://www.cdc.gov/EID/content/13/11/1794.htm
Please use the form below to submit correspondence to the authors or contact them at the following address:
Marcelo B. Labruna, Laboratório de Doenças Parasitárias, Departamento de Medicina Veterinária Preventiva e Saúde Animal, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, Av Prof Dr. Orlando Marques de Paiva 87, São Paulo, SP, Brazil 05508-270; email: labruna@usp.br
Please contact the EID Editors at eideditor@cdc.gov
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
This page posted October 29, 2007
This page last reviewed October 29, 2007
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435